Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

To assess the effects of dipeptidyl-peptidase (DDP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Secondary objectives are to analyse the strength and quality of the body of evidence for the associations between various definitions of 'prediabetes' (IGT, IFG, HbA1c thresholds) and the therapeutic consequences of DDP-4 inhibitors and GLP-1 analogues.

This is a protocol.

Share/Save